Mind Medicine (MindMed) (NASDAQ:MNMD) Stock Rating Upgraded by Roth Capital
Mind Medicine (MindMed) (NASDAQ:MNMD – Get Free Report) was upgraded by analysts at Roth Capital to a “strong-buy” rating in a research note issued to investors on Wednesday, Zacks.com reports. A number of other equities research analysts have also commented on the stock. HC Wainwright reiterated a “buy” rating and set a $35.00 price target […]
More Stories
Comparing AGC (OTCMKTS:ASGLY) & Sonic Healthcare (OTCMKTS:SKHHY)
AGC (OTCMKTS:ASGLY – Get Free Report) and Sonic Healthcare (OTCMKTS:SKHHY – Get Free Report) are both mid-cap industrial products companies,...
Comparing South Bow (SOBO) and Its Rivals
South Bow (NYSE:SOBO – Get Free Report) is one of 21 public companies in the “Pipelines, Except Natural Gas” industry,...
Trimedyne (OTCMKTS:TMED) Shares Cross Below 200 Day Moving Average – Here’s What Happened
Shares of Trimedyne, Inc. (OTCMKTS:TMED – Get Free Report) crossed below its two hundred day moving average during trading on...
Trimedyne (OTCMKTS:TMED) Shares Cross Below 200 Day Moving Average – Here’s What Happened
Shares of Trimedyne, Inc. (OTCMKTS:TMED – Get Free Report) crossed below its two hundred day moving average during trading on...
Trimedyne (OTCMKTS:TMED) Shares Cross Below 200 Day Moving Average – Here’s What Happened
Shares of Trimedyne, Inc. (OTCMKTS:TMED – Get Free Report) crossed below its two hundred day moving average during trading on...
DoubleLine Income Solutions Fund (NYSE:DSL) Shares Pass Below 200-Day Moving Average – Should You Sell?
Shares of DoubleLine Income Solutions Fund (NYSE:DSL – Get Free Report) passed below its 200-day moving average during trading on...